MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer

Oncotarget

Volumn 6, Issue 26, 2015, Pages 22996-23007

  Simmer, Femke ^a   Venderbosch, Sabine ^a,b   Dijkstra, Jeroen R ^a   Vink Börger, Elisa M ^a   Faber, Claudius ^c   Mekenkamp, Leonie J ^a   Koopman, Miriam ^d   De Haan, Anton F ^a   Punt, Cornelis J ^b   Nagtegaal, Iris D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biomarker; Chemotherapy; Colorectal cancer; Fluoropyrimidine; microRNA

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DICER; FLUOROPYRIMIDINE; IRINOTECAN; MEMBRANE PROTEIN; MICRORNA 103; MICRORNA 125B; MICRORNA 137; MICRORNA 140; MICRORNA 143; MICRORNA 145; MICRORNA 148A; MICRORNA 16; MICRORNA 18A; MICRORNA 191; MICRORNA 192; MICRORNA 19B; MICRORNA 21; MICRORNA 215; MICRORNA 222; MICRORNA 26B; MICRORNA 31; MICRORNA 34A; MICRORNA 92A; MICRORNA 93; MICRORNA LET7A; OXALIPLATIN; PROTEIN FXYD3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MICRORNA; MIRN143 MICRORNA, HUMAN; PLATINUM COMPLEX; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GENETICS; MALE; METABOLISM; METASTASIS; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CAMPTOTHECIN; CAPECITABINE; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941202014     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4035     Document Type: Article

References (38)

1. McArdle C. ABC of colorectal cancer: effectiveness of follow up. Bmj. 2000; 321:1332-1335.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N. Colorectal cancer. Lancet. 2010; 375:1030-1047.
3. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007; 370:135-142.
4. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH and Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? European journal of cancer. 2009; 45:1935-1949.
5. Czech B and Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nature reviews Genetics. 2011; 12:19-31.
6. Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, Boland CR and Goel A. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PloS one. 2012; 7:e46684.
7. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y and Mori M. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Annals of surgical oncology. 2012; 19:3065-3071.
8. Pichler M, Winter E, Stotz M, Eberhard K, Samonigg H, Lax S and Hoefler G. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. British journal of cancer. 2012; 106:1826-1832.
9. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA: the journal of the American Medical Association. 2008; 299:425-436.
10. Wei J, Liu LK, Gao W, Zhu CJ, Liu YQ, Cheng T and Shu YQ. Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2011; 23:123-128.
11. Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W and Qin H. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012; 61:1447-1453.
12. Hansen TF, Christensen R, Andersen RF, Sorensen FB, Johnsson A and Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. British journal of cancer. 2013; 109:1243-1251.
13. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, Pommier Y and Reinhold WC. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Molecular cancer therapeutics. 2010; 9:1080-1091.
14. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, Guenther SM, O'Leary JJ and Sheils O. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC biotechnology. 2007; 7:36.
15. Faber C, Horst D, Hlubek F and Kirchner T. Overexpression of Dicer predicts poor survival in colorectal cancer. European journal of cancer. 2011; 47:1414-1419.
16. Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, et al. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. European journal of cancer. 2013; 49:1501-1508.
17. Stratmann J, Wang CJ, Gnosa S, Wallin A, Hinselwood D, Sun XF and Zhang H. Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC cancer. 2011; 11:345.
18. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Hannon GJ, Lawson ND, Wolfe SA and Giraldez AJ. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010; 328:1694-1698.
19. Cheloufi S, Dos Santos CO, Chong MM and Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010; 465:584-589.
20. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ and Rodrigues CM. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. The FEBS journal. 2009; 276:6689-6700.
21. Zhu ZL, Zhao ZR, Zhang Y, Yang YH, Wang ZM, Cui DS, Wang MW, Kleeff J, Kayed H, Yan BY and Sun XF. Expression and significance of FXYD-3 protein in gastric adenocarcinoma. Disease markers. 2010; 28:63-69.
22. Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M and Asano S. FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. Biological & pharmaceutical bulletin. 2009; 32:1148-1154.
23. Widegren E, Onnesjo S, Arbman G, Kayed H, Zentgraf H, Kleeff J, Zhang H and Sun XF. Expression of FXYD3 protein in relation to biological and clinicopathological variables in colorectal cancers. Chemotherapy. 2009; 55:407-413.
24. Okudela K, Yazawa T, Ishii J, Woo T, Mitsui H, Bunai T, Sakaeda M, Shimoyamada H, Sato H, Tajiri M, Ogawa N, Masuda M, Sugimura H and Kitamura H. Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. The American journal of pathology. 2009; 175:2646-2656.
25. Loftas P, Onnesjo S, Widegren E, Adell G, Kayed H, Kleeff J, Zentgraf H and Sun XF. Expression of FXYD-3 is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy. International journal of radiation oncology, biology, physics. 2009; 75:137-142.
26. Kayed H, Kleeff J, Kolb A, Ketterer K, Keleg S, Felix K, Giese T, Penzel R, Zentgraf H, Buchler MW, Korc M and Friess H. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. International journal of cancer Journal international du cancer. 2006; 118:43-54.
27. Grzmil M, Voigt S, Thelen P, Hemmerlein B, Helmke K and Burfeind P. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. International journal of oncology. 2004; 24:97-105.
28. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ and Johnston PG. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer research. 2003; 63:4602-4606.
29. Sweadner KJ and Rael E. The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics. 2000; 68:41-56.
30. Geering K. Function of FXYD proteins, regulators of Na, K-ATPase. Journal of bioenergetics and biomembranes. 2005; 37:387-392.
31. Kaplan JH. Biochemistry of Na,K-ATPase. Annual review of biochemistry. 2002; 71:511-535.
32. Schmittgen TD and Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3:1101-1108.
33. Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ. miRBase: tools for microRNA genomics. Nucleic acids research. 2008; 36(Database issue):D154-158.
34. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120:15-20.
35. Huang da W, Sherman BT, Stephens R, Baseler MW, Lane HC and Lempicki RA. DAVID gene ID conversion tool. Bioinformation. 2008; 2:428-430.
36. Huang da W, Sherman BT and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009; 37:1-13.
37. Andersen CL, Jensen JL and Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer research. 2004; 64:5245-5250.
38. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology. 2002; 3:RESEARCH0034.